Celltheon

Celltheon's ground breaking ALTHEA(TM) platform leverages decades of antibody expression data in an end-to-end variant generation and fully automated AI-based in silico analysis of antibody structure pipeline. This first of its kind of pipeline enables immediate generation of hundreds of thousands of antibody variants, in silico screening and ranking, and downselection to identify likely candidates with improved binding, expression, reduced immunogenicity and more.

AI-Enabled Services:

• Antibody variant generation using ALTHEA(TM)

• Screening down to 5-20 top candidates optimized for expression, affinity, half-life, cell based binding characteristics, reduced immunogenicity, reduced nonspecific binding all in silico In vitro variant validation using state of the art developability assays including multispecies kinetics comparison, Fc kinetics assays, hydrophobicity and charge heterogeneity, in vitro models for half-life, aggregate quantification, low protein input aggregation potential in vitro model, high concentration stability and viscosity studies, polyreactivity, melting temperature, mass variants, stress testing, in vitro immunogenicity models Utilize Celltheon AI technologies in the following spaces:

  • Early candidate screening, including early variants screening in silico and in vitro, humanization, and high or low throughput variant generation and screening

  • Variant refinement, ensure best in class variant design through thorough lead candidate characterization and AI-enabled optimization of residual liabilities

• Research services that use machine learning (ML) algorithms

• Research services that use large language models (LLM)